Biolab and Sandoz Partner to Launch Semaglutide Pen for Type 2 Diabetes in Brazil
Biolab and Sandoz collaborate to introduce Owozy, a semaglutide pen approved by Anvisa, targeting Brazil's high type 2 diabetes population with weekly injectable treatment.
- • Biolab and Sandoz partner to launch Owozy, a semaglutide injectable pen in Brazil.
- • Owozy approved by Anvisa in July 2026 and expected in pharmacies by Q4 2026.
- • Targets adults with inadequately controlled type 2 diabetes, affecting over 26 million Brazilians.
- • Owozy is a multi-dose weekly injection with flexible storage conditions.
- • Biolab manages sales and promotion; Sandoz supplies the medication.
Key details
Biolab Farmacêutica and Swiss pharmaceutical company Sandoz have announced a partnership to commercialize and distribute Owozy, an injectable pen containing synthetic semaglutide, aimed at adults with inadequately controlled type 2 diabetes. The medication received approval from Brazil's National Health Surveillance Agency (Anvisa) in July 2026, alongside four other semaglutide products. Owozy is expected to be available in Brazilian pharmacies by the last quarter of 2026, marking a significant development in diabetes treatment accessibility within the country.
The drug will be sold in a multi-dose pen format intended for weekly administration. It features storage flexibility, maintaining stability for up to 24 months under refrigeration and up to 42 days at room temperature after removal from the fridge. This allows greater ease of use for patients.
Isabella Wanderley, president of Sandoz Brazil, emphasized the opportunity Owozy represents to improve access to high-quality therapeutic options for those managing type 2 diabetes. Biolab will oversee the promotion and sales strategies in Brazil, with Sandoz supplying the product.
Type 2 diabetes affects an estimated 12.9% of the Brazilian population, which translates to over 26 million diagnosed individuals, underscoring the potential impact of this new medication launch on public health.
This partnership comes amid a growing trend of synthetic semaglutide products entering the Brazilian market, aiming to address the increasing diabetes burden with effective treatment alternatives.
This article was translated and synthesized from Brazilian sources, providing English-speaking readers with local perspectives.
